An experimental therapy for A.L.S., the paralyzing and fatal neurological disorder also known as Lou Gehrig’s Disease, has been approved in Canada, adding a new treatment option for a disease for which there are few effective therapies. The FDA is currently reviewing the drug, and has raised questions about the treatment’s effectiveness.